Needham analyst Michael Matson maintained a Hold rating on Haemonetics (HAE – Research Report) today. The company’s shares opened today at $81.26.
According to TipRanks, Matson is an analyst with an average return of -2.3% and a 45.92% success rate. Matson covers the Healthcare sector, focusing on stocks such as Hologic, Masimo, and Atricure.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Haemonetics with a $97.50 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $95.26 and a one-year low of $74.13. Currently, Haemonetics has an average volume of 323.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics (HAE) Company Description:
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
Read More on HAE:
